Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that results from the ADACTA study will be presented on November 11 during an oral presentation at the 2012 American College of Rheumatology (ACR) Annual Scientific Meeting in Washington, D.C.
Results from the study showed ACTEMRA ® (tocilizumab) improved signs and symptoms (DAS28 score reduction) of rheumatoid arthritis (RA) significantly more than adalimumab when used alone as a single-agent therapy (without other disease-modifying antirheumatic drugs (DMARDs), including methotrexate).
RA patients are often treated with a combination of medicines that typically include a biologic medicine, such as ACTEMRA or adalimumab, plus methotrexate. However, about one in three patients on a biologic treatment such as ACTEMRA or adalimumab receive it as a single-agent therapy, largely due to intolerance to methotrexate.
"The goal of the ADACTA study was to evaluate the potential differences of ACTEMRA versus Humira when used as single-agent therapies for people with RA," said Hal Barron, M.D., chief medical officer and head, Global Product Development. “Data being presented at ACR further support the efficacy and safety profile of ACTEMRA."In addition to data from the ADACTA study, long-term follow-up of patients from AMBITION, a large Phase III study, will be presented at ACR. Together, these studies support the use of ACTEMRA alone as a single-agent therapy for RA patients who are either intolerant to methotrexate or in whom methotrexate use would not be appropriate. About the ADACTA Study (Abstract #772) ADACTA (ADalimumab ACTemrA) is a Phase IV multi-center, randomized, double-blind, parallel group study designed to compare the reduction in signs and symptoms of RA in adult patients treated with either ACTEMRA or adalimumab as a single-agent therapy. Patients participating in the study had severely active RA and either an intolerance to methotrexate or were not appropriate candidates for continued methotrexate treatment. Of note, patients participating in the study had not previously received a biologic medicine for RA.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV